Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies Amnon C. SintovLiron BerkovichShimon Ben-Shabat PRECLINICAL STUDIES 02 June 2012 Pages: 247 - 255
Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin Laurent SchwartzAdeline GuaisMohammad Abolhassani PRECLINICAL STUDIES 14 July 2012 Pages: 256 - 264
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258 Stefan ValloJens ManiRoman A. Blaheta PRECLINICAL STUDIES 17 July 2012 Pages: 265 - 272
The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models Céline ClémensonErwan JouannotEric Deutsch PRECLINICAL STUDIES 19 July 2012 Pages: 273 - 284
Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer Etchison RyanA. Jacobson BlakeA. Kratzke Robert PRECLINICAL STUDIES 22 July 2012 Pages: 285 - 292
Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line Roudy Chiminch EkyalongoToru MukoharaHironobu Minami PRECLINICAL STUDIES 25 July 2012 Pages: 293 - 303
Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor Anne-Sophie Belzacq-CasagrandeFlorence BachelotLaurent Désiré PRECLINICAL STUDIES 10 August 2012 Pages: 304 - 319
Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues Jintapat NateewattanaRungnapha SaeengPawinee Piyachaturawat PRECLINICAL STUDIES 17 August 2012 Pages: 320 - 332
Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation Elad MilrotAnna JackmanLevana Sherman PRECLINICAL STUDIES 06 September 2012 Pages: 333 - 344
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer Nilofer AzadArvind DasariWells A. Messersmith PHASE I STUDIES 22 May 2012 Pages: 345 - 354
A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies John F. GerecitanoJoe J. StephensonGary K. Schwartz PHASE I STUDIES 22 May 2012 Pages: 355 - 362
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET Jeffrey R. InfanteTerence RuggRamesh K. Ramanathan PHASE I STUDIES 01 May 2012 Pages: 363 - 369
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors Gary K. SchwartzRichard D. CarvajalGeoffrey I. Shapiro PHASE I STUDIES 02 June 2012 Pages: 370 - 380
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole L. A. DevrieseM. Mergui-RoelvinkJ. H. M. Schellens PHASE I STUDIES 05 May 2012 Pages: 381 - 389
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer C. Gómez-MartÃnR. SalazarJ. Bellmunt PHASE I STUDIES 22 May 2012 Pages: 390 - 398
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors John MarshallJimmy HwangNancy L Lewis PHASE I STUDIES Open access 17 November 2012 Pages: 399 - 408
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors Michael S. GordonDavid S. MendelsonDavid B. Agus PHASE I STUDIES Open access 15 December 2012 Pages: 409 - 416
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Tanguy SeiwertJohn SarantopoulosGeorge Blumenschein Jr. PHASE II STUDIES Open access 24 August 2012 Pages: 417 - 424
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma Patrick A. OttRichard D. CarvajalJedd D. Wolchok PHASE II STUDIES 05 August 2012 Pages: 425 - 434
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer Bryan J. SchneiderJulia Shin-Jung LeeSusan G. Urba PHASE II STUDIES 31 July 2012 Pages: 435 - 442
Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma Yumiko AoyamaAtsunori KaibaraTaiji Sawamoto PHASE II STUDIES Open access 16 August 2012 Pages: 443 - 451
The inhibitor of Ca2+-dependent K+ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB Christian FreiseMartin RuehlRajan Somasundaram Short Report 02 October 2012 Pages: 452 - 457
The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells Maria Grazia di IasioGiorgio Zauli SHORT REPORT 02 October 2012 Pages: 458 - 460
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines David DavidsonYunzhe WangLawrence Panasci SHORT REPORT 09 October 2012 Pages: 461 - 468
Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma Hee Kyung AhnSeok Jin KimWon Seog Kim SHORT REPORT 28 October 2012 Pages: 469 - 472
Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin Tetsuya TanimotoMasaharu TsubokuraMasahiro Kami REVIEW 11 September 2012 Pages: 473 - 478
Clinical trial design in biosimilar drug development G. DranitsarisK. DorwardE. Amir REVIEW 17 November 2012 Pages: 479 - 487
Erratum to: Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis Gopalakrishnan RamakrishnanSundaram JaganThiruvengadam Devaki Erratum 31 October 2012 Pages: 488 - 489
Erratum to: Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies Liron BerkovichAmnon C. SintovShimon Ben-Shabat Erratum 16 January 2013 Pages: 490 - 490